Table 1.
Demographic characteristics and outcomes of kidney transplant patients with immune checkpoint inhibitors for cancer treatment
| Variable | Total (N = 44) |
|---|---|
| Age, yr | 64±10 |
| Male sex | 35 (80) |
| Immune checkpoint inhibitor | |
| - Nivolumab | 15 (34) |
| - Pembrolizumab | 11 (25) |
| - Ipilimumab | 9 (20) |
| - Avelumab | 1 (2) |
| - Ipilimumab followed by pembrolizumab | 2 (5) |
| - Ipilimumab followed by nivolumab | 4 (9) |
| - Pembrolizumab followed by nivolumab | 1 (2) |
| - Pembrolizumab followed by ipilimumab | 1 (2) |
| Cancer | |
| - Melanoma | 30 (68) |
| - Lung cancer | 5 (11) |
| - Metastatic squamous cell carcinoma of skin | 5 (11) |
| - Merkel cell carcinoma | 2 (5) |
| - Urothelial carcinoma | 1 (2) |
| - Duodenal cancer | 1 (2) |
| Rejection | 18 (41) |
| Graft failure | 16/43a (37) |
| Cancer outcomes | |
| - Complete response | 5 (11) |
| - Partial response | 8 (18) |
| - Stable disease | 8 (18) |
| - Progressive disease | 21 (48) |
| - Not available | 2 (5) |
| Death | 18 (41) |
| Follow-up time | |
| - Less than 1 yr | 15 |
| - 1–3 yr | 5 |
a
One patient was excluded because he had graft failure due to transplant nephrectomy.